Nevirapine Use to Reduce Mother-To-Child Transmission of HIV in Canada | Zendy

Committee for Canadian Paediatric AIDS Research Group | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nevirapine Use to Reduce Mother-To-Child Transmission of HIV in Canada

Author(s) -

Committee for Canadian Paediatric AIDS Research Group

Publication year - 2001

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2001/319279

Subject(s) - nevirapine , rash , virology , reverse transcriptase , reverse transcriptase inhibitor , medicine , transmission (telecommunications) , nucleoside reverse transcriptase inhibitor , drug resistance , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , viral load , genetics , polymerase chain reaction , electrical engineering , gene , engineering

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used to treat adults and children with human immunodeficiency virus (HIV) infection. The drug was licensed in Canada in September 1998 and has been widely used in combination antiretroviral therapy regimens, usually along with two nucleoside reverse transcriptase inhibitors. NVP is, generally, well tolerated; however, up to 20% of patients may develop rash, with a severe rash occurring in 6% of patients and Stevens-Johnson syndrome reported in 0.5% of patients. A large number of NNRTI mutations have been documented, and a single mutation, K103N, confers a degree of broad NNRTI resistance. Distinctions occur in resistance patterns to different NNRTIs (1)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research